Genentech rethinks Avastin limits

Well, on second thought...maybe Genentech won't restrict supplies of Avastin. This turnabout announcement comes after the company met with eye specialists who were hopping mad that patients might be forced to buy Lucentis at $2,000 per dose versus Avastin at $40.

The company says it will need the FDA's OK to continue selling to compounding pharmacists who split Avastin vials into small doses for eye use. But it will postpone the distribution restrictions until January to give ophthalmologists time to find alternate sources.

- read the report from the San Francisco Chronicle

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.